Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [13558]

Novel antibody-drug conjugate eliminates residual cancer cells in majority of patients with B-cell ALL

Novel antibody-drug conjugate eliminates residual cancer cells in majority of patients with B-cell ALL

Scientists uncover why some patients with rare leukaemia may not benefit from approved targeted therapy

Scientists uncover why some patients with rare leukaemia may not benefit from approved targeted therapy

Study identifies a natural mechanism that limits tumour progression

Study identifies a natural mechanism that limits tumour progression

ESMO GI 2026: Blood test may help identify which colorectal cancer patients with liver metastases are most likely to benefit from chemotherapy after surgery

ESMO GI 2026: Blood test may help identify which colorectal cancer patients with liver metastases are most likely...

Rare benign kidney tumour case highlights value of biopsy and minimally invasive treatment

Rare benign kidney tumour case highlights value of biopsy and minimally invasive treatment

Do cancer screening rates differ across sexual orientation and gender identity?

Do cancer screening rates differ across sexual orientation and gender identity?

Biomarker-guided drug combinations may improve outcomes in treatment-resistant melanoma

Biomarker-guided drug combinations may improve outcomes in treatment-resistant melanoma

Uncovering gene-based clues to how disrupted healing in stomach cells increases cancer risk

Uncovering gene-based clues to how disrupted healing in stomach cells increases cancer risk

New laboratory tool opens door to better treatments for rare and deadly melanomas

New laboratory tool opens door to better treatments for rare and deadly melanomas

PLXNC1 – a novel biomarker for consensus molecular subtype 4 in colorectal cancer (CMS4 CRC)

PLXNC1 – a novel biomarker for consensus molecular subtype 4 in colorectal cancer (CMS4 CRC)

More from ecancer